Adam Cheifetz, MD, on Optimizing Treatment With Therapeutic Drug Monitoring

In this podcast, Adam Cheifetz, MD, a cochair of the virtual Interdisciplinary Autoimmune Summit (IAS) 2020, gives an overview of his presentation on how proactive and reactive therapeutic drug monitoring differ and how the proactive approach can significantly benefit patients with autoimmune diseases.

Adam Cheifetz, MD, is director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center in Boston, Massachusetts and professor of medicine at Harvard University Medical School.

For more coverage of the Interdisciplinary Autoimmune Summit, go to the IAS Newsroom.